Histogen Inc logo

HSTO - Histogen Inc News Story

$0.793 -0.0  -2.1%

Last Trade - 24/09/21

Sector
Healthcare
Size
Micro Cap
Market Cap £24.2m
Enterprise Value £6.56m
Revenue £1.03m
Position in Universe 6262nd / 7172

BUZZ-Histogen jumps on positive results from early-stage COVID-19 drug trial

Tue 22nd June, 2021 2:16pm
** Shares of clinical-stage therapeutics company  HSTO.O  up
10% premarket at $1.04 
    ** Co says early-stage study demonstrated that its
experimental drug, emricasan, was safe and well-tolerated in
mild symptomatic COVID-19 patients as compared with placebo,
with no reports of serious adverse events  urn:newsml:reuters.com:*:nGNX3TztVZ
    ** Study conducted along with partner Amerimmune LLC
    ** Patients who completed treatment with emricasan had a
complete resolution of the symptoms most commonly associated
with mild COVID-19, such as cough, headache and fatigue - co
    ** Up to Monday's close, stock has gained nearly 25% so far
this year
    

 (Reporting by Shashank Nayar in Bengaluru)
 ((Shashank.Nayar@thomsonreuters.com; within U.S. +1 646 223
8780; outside U.S. +91 80 6182 2256;))
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.